CardioDx Focused on CAD Test Adoption, Not IPO | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Having recently closed a financing round that brought in more than $40 million, CardioDx is not interested yet in going public, according to its CEO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.